undamentalytics Newsletter
Sign in

Precision Biosciences Inc revenue

Precision Biosciences Inc's revenue was $34.3m in fiscal 2025, down 50.1% on the year before. Since fiscal 2018 ($10.9m) it has grown at a compound 17.8% a year. Over the last twelve months it was $45.0m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue111,070241162549693445
Growth on the year before—+>999%−97.7%+375.7%−78.3%+94.1%+41.0%−50.1%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Precision Biosciences Inc $45.0m 6353.0% -4.9%
Sutro Biopharma, Inc. $45.7m -56.3% -7.0%
Spero Therapeutics, Inc. $47.0m -3.3% -4.7%
Editas Medicine, Inc. $47.0m 20.8% 34.5%
Lexicon Pharmaceuticals, Inc. $41.5m -29.0% 366.7%
Ocular Therapeutix, Inc $52.1m -8.1% -1.6%

Compare with peers

Head to head: DTIL vs STRODTIL vs SPRODTIL vs EDIT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Precision Biosciences Inc's SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Precision Biosciences Inc.